Vitamin D and the Health of Blood Vessels in Kidney Disease

NCT01247311

Last updated date
Study Location
St Paul's Hospital & Vancouver General Hospital
Vancouver, British Columbia, , Canada
Contact
1-800-718-1021

FOR MORE INFORMATION

Contact a representative by phone, email, or visiting the study website. Please see the references below:

By phone

Pfizer Clinical Trials Contact Center

1-800-718-1021

By email

Contact

[email protected]

Call Now

Eligibility Criteria
condition
The disease, disorder, syndrome, illness, or injury that is being studied.
Chronic Kidney Disease (CKD)
Sex
Females and Males
Age
Pediatric Trials: 0-17 Years
Adult Trials: 18+ Years
19 + years
Inclusion Criteria
The factors, or reasons, that allow a person to participate in a clinical study.
Show details

- patients with an estimated glomerular filtration rate (eGFR) between 15 - 45 ml/min, and <2ml/min change in glomerular filtration rate (GFR) over the past 6 months

- treated with maximal conventional cardiovascular disease (CVD) risk reduction medications

Exclusion Criteria
The factors, or reasons, that prevent a person from participating in a clinical study.
Show details


- patients with estimated glomerular filtration rate (eGFR) change of >2.1 ml/min over
the past 6 months


- those who have terminal malignancies


- those with planned transplant within 6 months, or who are likely to commence renal
replacement therapy (dialysis) within the 6 months after enrolment


- those with active infections or active inflammatory diseases (Systemic Lupus
Erythematosus (SLE), vasculitis)


- those who refuse to give informed consent

NEED INFO?

Questions about a trial? Call or email to reach a Pfizer Clinical Trial Contact Center Representative

Pfizer Clinical Trials Contact Center

1-800-718-1021

[email protected]

TRY A NEW SEARCH

Search for Clinical Trials by condition, keyword or trial number. Share your location or enter your city or zip code to find studies near you.

Based on your search, you may also be interested in

Chronic Kidney Disease (CKD)Vitamin D and the Health of Blood Vessels in Kidney Disease
NCT01247311
  1. Vancouver, British Columbia
ALL GENDERS
19 Years+
years
MULTIPLE SITES
Chronic Kidney Disease (CKD)A Phase 3b Study of Erythropoietin Drugs Using a Specified Dosing Algorithm in Patients With Chronic Kidney Disease on Hemodialysis
NCT02504294
  1. Chula Vista, California
  2. Poway, California
  3. Rancho Bernardo, California
  4. San Diego, California
  5. San Diego, California
  6. Tampa, Florida
  7. Tampa, Florida
  8. Tampa, Florida
  9. Boise, Idaho
  10. Boise, Idaho
  11. Caldwell, Idaho
  12. Caldwell, Idaho
  13. Meridian, Idaho
  14. Meridian, Idaho
  15. Nampa, Idaho
  16. Nampa, Idaho
  17. Kalamazoo, Michigan
  18. Kalamazoo, Michigan
  19. Kalamazoo, Michigan
  20. Biloxi, Mississippi
  21. Gulfport, Mississippi
  22. Gulfport, Mississippi
  23. Charlotte, North Carolina
  24. Charlotte, North Carolina
  25. Durham, North Carolina
  26. Durham, North Carolina
  27. Matthews, North Carolina
  28. Lansdale, Pennsylvania
  29. Philadelphia, Pennsylvania
  30. Warwick, Rhode Island
  31. Crossville, Tennessee
  32. Franklin, Tennessee
  33. Knoxville, Tennessee
  34. Knoxville, Tennessee
  35. Nashville, Tennessee
  36. Austin, Texas
  37. Austin, Texas
  38. Houston, Texas
  39. Houston, Texas
  40. McAllen, Texas
  41. Rosenberg, Texas
  42. Weslaco, Texas
  43. Carolina,
  44. Humacao,
  45. San Juan,
ALL GENDERS
18 Years+
years
MULTIPLE SITES
Advanced Information
Descriptive Information
Brief Title  ICMJE Vitamin D and the Health of Blood Vessels in Kidney Disease
Official Title  ICMJE The Impact of Vitamin D Supplementation on Vascular Stiffness and Blood Pressure in Chronic Kidney Disease Patients
Brief Summary Individuals with kidney disease have a high risk of heart disease. This is not related to traditional risk factors, such as high blood pressure, high cholesterol or being overweight. A lack of vitamin D could be the reason why blood vessels become damaged and could explain the link between heart disease and kidney disease.
Detailed Description

Most people living in Canada do not receive enough vitamin D from the sun or from the food they eat. When a person has kidney disease this is a particular problem as kidney disease stops what little vitamin D we do have being activated in the body. Low levels of activated vitamin D causes a domino effect with calcium and phosphate and all the hormones that control calcium and phosphate. Some people believe that this imbalance damages the blood vessels causing them to become stiff and inflexible (arterial stiffness) and this in turn could cause heart disease. In addition there are two different types of vitamin D that can be prescribed and it is currently not known whether there is any difference between the two types of vitamin D and the effect they have on the blood vessels.

The purpose of this study is to investigate whether providing vitamin D as a medication can have a direct affect on the stiffness of the blood vessels. The findings of this study will help both physicians and dietitians decide whether Vitamin D therapy is beneficial to patients and should help decide which type of Vitamin D is best to give to people with chronic kidney disease (CKD).

Study Type  ICMJE Interventional
Study Phase  ICMJE Not Applicable
Study Design  ICMJE Allocation: Randomized
Intervention Model: Single Group Assignment
Masking: Double (Participant, Investigator)
Primary Purpose: Treatment
Condition  ICMJE Chronic Kidney Disease (CKD)
Intervention  ICMJE
  • Dietary Supplement: Dietary supplement
    Placebo given orally 3xweek for six months
  • Dietary Supplement: Vitamin D
    5000 IU vitamin D given orally 3xweek for six months
  • Dietary Supplement: Vitamin D
    0.5ug 1,25 vitamin D given orally 3xweek for six months
Study Arms  ICMJE
  • Active Comparator: 1.

    1,25 Vitamin D (0.50ug *3 per week)

    This is a prospective randomized double blind placebo controlled study of 125 stable CKD subjects examining the impact of vitamin D supplementation (1,25 vitamin D or 25 vitamin D formulations) compared to placebo on arterial stiffness and other parameters of vascular health

    Intervention: Dietary Supplement: Vitamin D
  • Active Comparator: 2.

    25 Vitamin D (5000IU * 3 per week)

    This is a prospective randomized double blind placebo controlled study of 125 stable CKD subjects examining the impact of vitamin D supplementation (1,25 vitamin D or 25 vitamin D formulations) compared to placebo on arterial stiffness and other parameters of vascular health

    Intervention: Dietary Supplement: Vitamin D
  • Placebo Comparator: 3.
    Placebo given orally 3xweek for six months
    Intervention: Dietary Supplement: Dietary supplement
Publications *

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Recruitment Information
Recruitment Status  ICMJE Completed
Actual Enrollment  ICMJE
 (submitted: September 23, 2014)
129
Original Estimated Enrollment  ICMJE
 (submitted: November 22, 2010)
125
Actual Study Completion Date  ICMJE August 2014
Actual Primary Completion Date August 2014   (Final data collection date for primary outcome measure)
Eligibility Criteria  ICMJE

Inclusion Criteria:

  • patients with an estimated glomerular filtration rate (eGFR) between 15 - 45 ml/min, and <2ml/min change in glomerular filtration rate (GFR) over the past 6 months
  • treated with maximal conventional cardiovascular disease (CVD) risk reduction medications

Exclusion Criteria:

  • patients with estimated glomerular filtration rate (eGFR) change of >2.1 ml/min over the past 6 months
  • those who have terminal malignancies
  • those with planned transplant within 6 months, or who are likely to commence renal replacement therapy (dialysis) within the 6 months after enrolment
  • those with active infections or active inflammatory diseases (Systemic Lupus Erythematosus (SLE), vasculitis)
  • those who refuse to give informed consent
Sex/Gender  ICMJE
Sexes Eligible for Study:All
Ages  ICMJE 19 Years and older   (Adult, Older Adult)
Accepts Healthy Volunteers  ICMJE No
Contacts  ICMJE Contact information is only displayed when the study is recruiting subjects
Listed Location Countries  ICMJE Canada
Removed Location Countries  
 
Administrative Information
NCT Number  ICMJE NCT01247311
Other Study ID Numbers  ICMJE H10-01689
Has Data Monitoring Committee Yes
U.S. FDA-regulated Product Not Provided
IPD Sharing Statement  ICMJE Not Provided
Responsible Party University of British Columbia
Study Sponsor  ICMJE University of British Columbia
Collaborators  ICMJE
  • The Kidney Foundation of Canada
  • Pfizer
Investigators  ICMJE
Principal Investigator:Adeera Levin, Dr.University of British Columbia
PRS Account University of British Columbia
Verification Date June 2017

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP